• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 17, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research